Skip to main content
Premium Trial:

Request an Annual Quote

Sangamo, Icagen Pen Protein-Transcription Collaboration

NEW YORK, July 17 - Sangamo Biosciences said today it will develop certain cell lines for high-throughput small-molecule screening for drug developer Icagen.

 

Under the deal, Sangamo will use its zinc finger DNA-binding protein-transcription factor technology to build cell lines that overexpress certain proteins.

 

Click here for more information.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.